FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 182 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1 | -50.0% | 360 | 0.0% | 0.00% | – |
Q2 2023 | $2 | 0.0% | 360 | 0.0% | 0.00% | – |
Q1 2023 | $2 | -50.0% | 360 | 0.0% | 0.00% | – |
Q4 2022 | $4 | -100.0% | 360 | 0.0% | 0.00% | – |
Q3 2022 | $8,000 | -11.1% | 360 | 0.0% | 0.00% | – |
Q2 2022 | $9,000 | -18.2% | 360 | +29.0% | 0.00% | – |
Q1 2022 | $11,000 | -31.2% | 279 | 0.0% | 0.00% | – |
Q4 2021 | $16,000 | -15.8% | 279 | -14.4% | 0.00% | – |
Q3 2021 | $19,000 | +18.8% | 326 | +75.3% | 0.00% | – |
Q2 2021 | $16,000 | +6.7% | 186 | 0.0% | 0.00% | – |
Q1 2021 | $15,000 | 0.0% | 186 | +13.4% | 0.00% | – |
Q4 2020 | $15,000 | -25.0% | 164 | -66.5% | 0.00% | – |
Q3 2020 | $20,000 | +122.2% | 490 | +19.5% | 0.00% | – |
Q2 2020 | $9,000 | 0.0% | 410 | 0.0% | 0.00% | – |
Q1 2020 | $9,000 | +12.5% | 410 | 0.0% | 0.00% | – |
Q4 2019 | $8,000 | +33.3% | 410 | 0.0% | 0.00% | – |
Q3 2019 | $6,000 | -25.0% | 410 | 0.0% | 0.00% | – |
Q2 2019 | $8,000 | +14.3% | 410 | 0.0% | 0.00% | – |
Q1 2019 | $7,000 | 0.0% | 410 | -25.5% | 0.00% | – |
Q4 2018 | $7,000 | – | 550 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |